Pathogenesis and novel therapeutics of regulatory T cell subsets and interleukin-2 therapy in systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a heterogeneous multisystem inflammatory disease with wide variability in clinical manifestations. Natural arising CD4+ regulatory T cells (Tregs) play a critical role in maintaining peripheral tolerance by suppressing inflammation and preventing autoimmune resp...
Main Authors: | Yi-Giien Tsai, Pei-Fen Liao, Kai-Hung Hsiao, Hung-Ming Wu, Ching-Yuang Lin, Kuender D. Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1230264/full |
Similar Items
-
Correlation of plasma interleukin-18 concentration and severity of renal involvement and disease activity in systemic lupus erythematosus
by: Mohammad Reza Jafari-Nakhjavani, et al.
Published: (2016-01-01) -
Efficacy, safety and the lymphocyte subsets changes of low‐dose IL‐2 in patients with systemic lupus erythematosus: A systematic review and meta‐analysis
by: Qin‐Yi Su, et al.
Published: (2024-01-01) -
T Cells, Interleukin-2 and Systemic Lupus Erythematosus—From Pathophysiology to Therapy
by: Anselm Mak
Published: (2022-03-01) -
Concomitant use of interleukin-2 and tacrolimus suppresses follicular helper T cell proportion and exerts therapeutic effect against lupus nephritis in systemic lupus erythematosus-like chronic graft versus host disease
by: Yutaro Nasa, et al.
Published: (2024-04-01) -
Exploratory study of serum IL-36 subfamily as biomarkers of disease progression in lupus nephritis
by: Chao Liu, et al.
Published: (2023-10-01)